StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
114450.KQ$2430.00-4.89%
Fair $2430.00+0.0%

114450.KQ

KPX Lifescience.Co.,Ltd.

Unknown / UnknownKOSDAQ

$2430.00

-125.00 (-4.89%)

Fairly Valued+0.0%Fair Value $2430.00Fund rank 26/100 · Data gapFallback financials|
SA 32/D
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-105.0M · quality 45.3/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

32/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 0.3%, below the 5% threshold
Thesis & Journal · 114450.KQLocal privado en este navegador · KPX Lifescience.Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$46.4B

P/E

405.0x

↑

EV/EBITDA

33.4x

↑

ROE

0.3%

↓

Gross Margin

6.1%

↓

Debt/Equity

0.18

↓
52-Week Range$2430
$1652$4640

TradingView lightweight chart

114450.KQ price, volumen y niveles de valoración

Último $2,430Periodo -49.8%
Fair value: $2,430

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+3.4%

FCF CAGR

—

FCF margin

-2.0%

FCF / Net income

-7.23x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $40.34B · net income $110.1M · FCF $-796.4M

2022-FY → 2025-FY

Gross margin

6.1%+9.8% pts

Operating margin

0.5%+11.3% pts

Net margin

0.3%+9.9% pts

FCF margin

-2.0%+14.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$40.34B$40.34B$24.86B$22.37B$36.50B
Net Income$110.1M$110.1M$1.56B$-16.36B$-3.53B
EBITDA$1.14B$1.14B$2.57B$-13.64B$21.9M
EPS6.006.0081.00-820.00-132.00
Gross Margin6.1%6.1%12.0%-10.3%-3.7%
Operating Margin0.5%0.5%1.5%-20.8%-10.8%
Net Margin0.3%0.3%6.3%-73.1%-9.7%
Balance Sheet
Debt/Equity0.180.180.150.140.13
Cash Flow
Free Cash Flow$-796.4M$-796.4M$62.8M$-105.0M$-6.03B
Returns
ROE0.3%0.3%4.4%-45.5%-6.7%
Valuation
P/E405.00405.0020.57——
EV/EBITDA33.4433.4411.07—4107.91
P/B1.161.160.901.251.64
Growth & Yield
Revenue Growth62.3%62.3%11.1%-38.7%—
EPS Growth-92.6%-92.6%109.9%-521.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

230.0%

muy exigente

EPS terminal req.

$215.62

Spread vs growth

-322.6%

5Y implied EPS CAGR

112.7%

muy exigente

EPS terminal req.

$260.90

Spread vs growth

-205.2%

10Y implied EPS CAGR

52.9%

muy exigente

EPS terminal req.

$420.19

Spread vs growth

-145.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +43.0%

Total return

+43.0%

Start / end P/E

21.0x → 405.0x

EPS bridge

81.00 → 6.00

Residual

-1695.2%

EPS growth-92.6%
Multiple rerating+1830.8%
Dividend+0.0%
Residual / FX / buybacks / cross-term-1695.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.